This week in oncology news, the FDA granted approval to belantamab mafodotin-blmf (GSK2857916; Blenrep), an immunoconjugate targeted B-cell maturation antigen, for the treatment of relapsed/refractory multiple myeloma and to tafasitamab-cxix (Monjuvi) plus lenalidomide (Revlimid) as treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
A Biologics License Application was also submitted to the FDA for omburtamab, which is intended for the treatment of pediatric patients with central nervous system (CNS)/leptomeningeal metastasis from neuroblastoma. A Fast Track designation was also granted to BST-236 for the treatment of older adult patients with acute myeloid leukemia. An Orphan Drug designation was also granted to SM-88 for the treatment of patients with pancreatic cancer.
FDA Approves Belantamab Mafodotin for Relapsed or Refractory Multiple Myeloma
The FDA granted approval to belantamab mafodotin-blmf for the treatment of patients with relapsed or refractory multiple myeloma who previously received treatment with at least 4 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody.
FDA Approves Tafasitamab/Lenalidomide for R/R DLBCL
The FDA granted approval to the combination oftafasitamab-cxix plus lenalidomide for the treatment of adultpatients with relapsed or refractory DLBCLnot otherwise specified, including DLBCL arising from low-grade lymphoma, and patients who are not eligible for autologous stem cell transplant.
Cellular Therapies Provide Hopeful Outcomes as Treatment of Patients with Myeloma
In an interview with Targeted Oncology, C. Ola Landgren, MD, PhD, discussed the development of CAR T-cell therapy in the treatment landscape of multiple myeloma.
Salvage Blinatumomab Therapy Generates Durable Responses in Relapsed/Refractory DLBCL
Salvage therapy with blinatumomab (Blincyto) may induce durable complete responses and a survival benefit as treatment of patients with relapsed/refractory diffuse large B-cell lymphoma, according to findings from a pooled analysis of 3 clinical trials.
FDA Grants Orphan Drug Designation for SM-88 for Treatment of Pancreatic Cancer
The FDA has granted an Orphan Drug designation to SM-88 for the potential treatment of patients with pancreatic cancer.
Multiple Therapies Show Responses in Lung Cancer With ROS1 Fusions
Ben Levy, MD, discusses the mechanism of resistance such as the G2032R solvent front mutation in patients who received crizotinib (Xalkori) for lung cancer with ROS1 fusions and how to treat them.
Expert Perspective Tumor Board: Hepatocellular Carcinoma
In this series, Ghassan Abou-Alfa, MD, MBA, and a group of experts discuss the treatment landscape of patients with hepatocellular carcinoma in 4 separate case discussions.
Recommendations for Managing Patients With Lung Cancer During COVID-19 Era
In response to the COVID-19 pandemic, the European Society of Medical Oncology has published recommendations for the management of patients with lung cancer to maintain high-quality standards of treatment.
See the original post here:
Trending News on Targeted Oncology, Week of August 7, 2020 – Targeted Oncology